Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial

Mi Mi Ko, Mi-Kyung Jeong (), Chang Min Choi, Seung Hyeun Lee, Jaemoo Chun, Jin-Mu Yi, Ho Jang and Sung Yong Lee ()
Additional contact information
Mi Mi Ko: KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
Mi-Kyung Jeong: KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
Chang Min Choi: Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 05505, Republic of Korea
Seung Hyeun Lee: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul 02447, Republic of Korea
Jaemoo Chun: KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
Jin-Mu Yi: KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
Ho Jang: KM Data Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
Sung Yong Lee: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea

IJERPH, 2023, vol. 20, issue 5, 1-12

Abstract: Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is a major treatment option for several types of cancer, including non-small cell lung cancer (NSCLC). The proposed study aims to investigate the safety and efficacy of Bojungikki-tang (BJIKT) therapy (an herbal medicine) in patients with advanced NSCLC treated with ICIs. This multicenter, randomized, placebo-controlled pilot study will be performed at three academic hospitals. Thirty patients with advanced NSCLC, undergoing atezolizumab monotherapy as second- and subsequent-line treatment, will be recruited and randomly assigned to either BJIKT treatment (atezolizumab + BJIKT) or placebo (atezolizumab + placebo). The primary and secondary outcomes are the incidence of adverse events (AEs), including immune- related AEs (irAEs) and non-immune-related AEs (non-irAEs); and early termination rate, withdrawal period, symptom improvement of fatigue, and skeletal muscle loss, respectively. The exploratory outcomes are patient objective response rate and immune profile. This is an ongoing trial. Recruitment started on 25 March 2022 and is expected to be completed by 30 June 2023. This study will provide basic evidence for the safety profiles, including irAEs, of herbal medicine in patients with advanced NSCLC treated with ICIs.

Keywords: Bojungikki-tang; immune checkpoint inhibitors; non-small cell lung cancer (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/5/4507/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/5/4507/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:5:p:4507-:d:1086645

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().